
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX is a promising company with a strong human diagnostics and monitoring focus, backed by revolutionary science and a dedicated team. However, recent reverse split actions may have negatively impacted stock value, shareholder base and liquidity, requiring time to repair and potentially indicating further shareholder concerns for the future. As an analyst it would be important to closely monitor future financial reports and announcements to fully assess the impact of the reverse split on the company's long-term growth potential.
Bears say
VolitionRX is facing several risks to achieving success, including potential barriers to regulatory or clinical approval, financial hurdles and potential market share losses. Although the company's recent study showed promise in detecting cancer, a concerning level of debt and the need for future capital raises could add significant pressure to the stock. Furthermore, competition in the liquid biopsy market and the company's struggle to establish commercial traction could impede its growth potential.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares